home / stock / grts / grts articles
-- High neutralizing antibody (nAb) responses sustained through at least 12 months, highlighting potential for durable clinical protection -- -- T...
Gainers Applied UV, Inc. (NASDAQ: AUVI) gained 60.4% to $0.4924. Applied UV said its new product, the Airocide® Pro+ air purification system f...
EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to devel...
Gainers Inpixon (NASDAQ: INPX) shares rose 44.6% to $0.2023 in pre-market trading after gaining around 10% on Wednesday. Gritstone bio, Inc. (NASD...
Gritstone Bio Inc (NASDAQ: GRTS) received a contract from the Biomedical Advanced Research and Development Authority (BARDA) to conduct a Phas...
EMERYVILLE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to deve...
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
2024-06-14 13:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for GRTS on June 14, 2024 11:01AM ET. The previous analyst recommendation was Market Outperform. GRTS was trading at $0.7575 at issue of the analyst recommendation. The overall analyst ...
2024-05-24 11:30:04 ET B. Riley analyst issues BUY recommendation for GRTS on May 24, 2024 09:31AM ET. The previous analyst recommendation was Buy. GRTS was trading at $0.8039 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024...